By 2020 the CBD market may hit the $2 billion mark.
CBD, unlike THC, isn’t psychoactive and those that use it won’t get “high.” Because of an ever increasing demand for CBD, the market is growing fast. The reason behind this increase is due to scientific and anecdotal evidence of the effect that CBD has on a variety of concerns, including anxiety, pain, inflammation, nausea and seizures. Not to mention that high value it holds in fighting the opioid crisis. This white paper reviews the relevant legal landscape and relevant federal agencies when comparing marijuana versus industrial hemp; as well as how the DEA and FDA are working with CBD.
You can Login to access if you are already registered.
Thank You!
Download White PaperMore Program Information
